Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunologic cytotoxicity [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Clinical Study on Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.
The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
100 Clinical Results associated with Guangdong GD Kongming Biotech LLC.
0 Patents (Medical) associated with Guangdong GD Kongming Biotech LLC.
100 Deals associated with Guangdong GD Kongming Biotech LLC.
100 Translational Medicine associated with Guangdong GD Kongming Biotech LLC.